Breast Cancer | Meet The Professor: Optimizing the Management of ER-Positive and Triple-Negative Breast Cancer — Part 2 of a 3-Part Series
Featuring perspectives from Dr Sara Tolaney, including the following topics: • Introduction (00:00) • Case: A premenopausal woman in her early 30s with T1c N0 ER/PR-positive, HER2-negative, gBRCA2-mutant invasive ductal carcinoma (IDC) with an Oncotype DX® Recurrence Score® (RS) of 30 receives adjuvant chemotherapy followed by leuprolide/letrozole but wishes to discontinue treatment to attempt pregnancy — Alan B Astrow, MD (10:19) • Case: A woman in her late 30s with T2 N0 ER/PR-positive, HER2-negative IDC and RS of 35 has severe menopause after adjuvant TC, TAH/BSO and letrozole — Ranju Gupta, MD (22:18) • Case: A postmenopausal woman in her early 50s with bilateral ER-positive, HER2-negative breast cancer; RS on the left is low and on the right is 30 but the tumor is 4 millimeters — Zanetta S Lamar, MD (34:19) • Case: A premenopausal woman in her early 40s with a gBRCA2 mutation and Stage IIB ER/PR-positive, HER2-low (IHC 1+) IDC treated with adjuvant tamoxifen develops extensive metastases and receives ovarian function suppression, letrozole and palbociclib — Jeremy Lorber, MD (38:57) • Case: A woman in her early 70s with multiregimen-recurrent ER/PR-positive, HER2-low (IHC 1+) metastatic breast cancer receives T-DXd — Henna Malik, MD (54:25) • Case: A woman in her mid 40s with node-positive localized triple-negative breast cancer has residual disease after neoadjuvant pembrolizumab/chemotherapy and surgery — Laila Agrawal, MD (57:05) CME information and select publications